A study of clinical and molecular characteristics in bilateral primary breast cancer

Bilateral primary breast cancer (BPBC) is a rare type of breast cancer. Studies on the clinicopathologic and molecular characteristics of BPBC in a metastatic context are very limited.

[1]  O. Mariani,et al.  Evolution of synchronous female bilateral breast cancers and response to treatment , 2023, Nature Medicine.

[2]  Jack A. Taylor,et al.  Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Linfu Xie,et al.  Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples , 2022, Molecular Diagnosis & Therapy.

[4]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  Xiaoyan Zhou,et al.  Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions , 2021, Frontiers in Genetics.

[6]  Ting Li,et al.  Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers , 2021, Frontiers in Oncology.

[7]  Jamie R. Kutasovic,et al.  The Genomic Landscape of Lobular Breast Cancer , 2021, Cancers.

[8]  M. Lux,et al.  Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yitong Wang,et al.  Clinical characteristics and clinicopathological correlations of bilateral breast cancer in China: A multicenter study from Chinese Society of Breast Surgery (CSBrS-006) , 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[10]  B. Ramaswamy,et al.  Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. , 2021, The oncologist.

[11]  R. Tamimi,et al.  Tumor phenotype and concordance in synchronous bilateral breast cancer in young women , 2020, Breast Cancer Research and Treatment.

[12]  S. Novaković,et al.  Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients , 2020, Annals of Surgical Oncology.

[13]  Ting Li,et al.  Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients , 2020, Frontiers in Oncology.

[14]  T. Pal,et al.  Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers , 2020, Breast Cancer Research and Treatment.

[15]  A. Tjønneland,et al.  Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology , 2020, Breast Cancer Research and Treatment.

[16]  Z. Shao,et al.  Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer , 2020, Frontiers in Oncology.

[17]  W. Han,et al.  Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[18]  E. Imyanitov,et al.  Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes , 2019, Expert review of molecular diagnostics.

[19]  M. Golshan,et al.  National trends of synchronous bilateral breast cancer incidence in the United States , 2019, Breast Cancer Research and Treatment.

[20]  Qingli Zhu,et al.  The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018) , 2019, Cancer medicine.

[21]  H. Struikmans,et al.  Bilateral breast cancer, synchronous and metachronous; differences and outcome , 2015, Breast Cancer Research and Treatment.

[22]  C. Napoli,et al.  A novel PALB2 truncating mutation in an Italian family with male breast cancer. , 2015, Oncology reports.

[23]  S. Narod.  Bilateral breast cancers , 2014, Nature Reviews Clinical Oncology.

[24]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[25]  U. Güth,et al.  Prognosis of early-stage synchronous bilateral invasive breast cancer. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[26]  O. Olopade,et al.  Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers , 2011, British Journal of Cancer.

[27]  Nicola Miller,et al.  Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics , 2011, Breast Cancer Research and Treatment.

[28]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[29]  E. Imyanitov,et al.  Microsatellite instability analysis of bilateral breast tumors suggests treatment-related origin of some contralateral malignancies , 2006, Journal of Cancer Research and Clinical Oncology.

[30]  U. Demirci,et al.  Clinicopathological features in bilateral breast cancer. , 2012, Asian Pacific journal of cancer prevention : APJCP.